BAX Share Price

Open 60.92 Change Price %
High 61.07 1 Day -0.29 -0.48
Low 60.59 1 Week 0.64 1.07
Close 60.69 1 Month 2.05 3.50
Volume 2547013 1 Year 17.31 39.90
52 Week High 61.52
52 Week Low 43.13
BAX Important Levels
Resistance 2 61.13
Resistance 1 60.95
Pivot 60.78
Support 1 60.43
Support 2 60.25
NYSE USA Most Active Stocks
EMC 29.05 0.97%
EMC 29.05 0.97%
EMC 29.05 0.97%
AMD 13.40 -4.83%
AMD 13.40 -4.83%
AMD 13.40 -4.83%
BAC 23.27 1.66%
BAC 23.27 1.66%
BAC 23.27 1.66%
SE 40.68 -0.78%
More..
NYSE USA Top Gainers Stocks
CBI 20.02 39.03%
CBI 20.02 39.03%
POM 26.93 26.79%
POM 26.93 26.79%
GLF 0.34 25.93%
GLF 0.34 25.93%
FNP 35.24 12.02%
FNP 35.24 12.02%
AUO 4.81 9.57%
AUO 4.81 9.57%
More..
NYSE USA Top Losers Stocks
ENL 15.81 -66.25%
ENL 15.81 -66.25%
ENL 15.81 -66.25%
MHR 0.15 -42.31%
MHR 0.15 -42.31%
MHR 0.15 -42.31%
STP 0.53 -39.77%
STP 0.53 -39.77%
STP 0.53 -39.77%
STP 0.53 -39.77%
More..

Baxter International Inc. (NYSE: BAX)

BAX Technical Analysis 5
As on 27th Jun 2017 BAX Share Price closed @ 60.69 and we RECOMMEND Strong Buy for LONG-TERM with Stoploss of 49.94 & Strong Buy for SHORT-TERM with Stoploss of 56.99 we also expect STOCK to react on Following IMPORTANT LEVELS.
BAX Target for June
1st Target up-side 61.73
2nd Target up-side 63.43
3rd Target up-side 65.12
1st Target down-side 56.89
2nd Target down-side 55.19
3rd Target down-side 53.5
BAX Other Details
Segment EQ
Market Capital 36252073984.00
Sector Healthcare
Industry Medical Instruments & Supplies
Offical website http://www.baxter.com
BAX Address
BAX
One Baxter Parkway
Deerfield, IL 60015
United States
Phone: 224-948-2000
Fax: 224-948-1813
BAX Latest News
Interactive Technical Analysis Chart Baxter International Inc. ( BAX NYSE USA )
Java support must be enabled in order to display FnCharts.
You can download Java from http://www.java.com
Your Comments and Response on Baxter International Inc.
BAX Business Profile
Baxter International Inc. develops, manufactures, and markets products for people with hemophilia, immune disorders, infectious diseases, kidney diseases, trauma, and other chronic and acute medical conditions. Its BioScience segment processes recombinant and plasma-based proteins to treat hemophilia and other bleeding disorders; plasma-based therapies to treat immune deficiencies, alpha-1 antitrypsin deficiency, burns and shock, and other chronic and acute blood-related conditions; biosurgery products; and certain vaccines. The company’s Medical Products segment manufactures intravenous (IV) solutions and administration sets, premixed drugs and drug-reconstitution systems, pre-filled vials and syringes for injectable drugs, IV nutrition products, infusion pumps, and inhalation anesthetics; products and services related to pharmacy compounding, drug formulation, and packaging technologies; and technologies and therapies for peritoneal dialysis, in-center and home hemodialysis, and continuous renal replacement therapy. It sells its products through its direct sales force, independent distributors, drug wholesalers, and specialty pharmacy or other alternate site providers to hospitals, kidney dialysis and rehabilitation centers, nursing homes, doctors’ offices, clinical and medical research laboratories, and patients. The company has collaboration with Cell Therapeutics, Inc. to develop and commercialize pacritinib; Coherus Biosciences, Inc. and Momenta Pharmaceuticals, Inc. to develop and commercialize biosimilars; JW Holdings Corporation for parenteral nutritional products containing a formulation of omega 3 lipids; Onconova Therapeutics, Inc. for rigosertib, an anti-cancer compound; and Chatham Therapeutics, LLC to develop and commercialize product for the treatments of hemophilia B. It operates in the United States, Europe, the Middle East, Africa, the Asia-Pacific, Latin America, and Canada. The company was founded in 1931 and is based in Deerfield, Illinois.